

Title: Oesophageal & Gastric Cancer Treatments

Reference Number: RDF1359-23

Date of Response: 05/04/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon and Exeter NHS Foundation Trust,

I am researching the incidence and treatment of oesophageal and gastric cancer. I would greatly appreciate if you could answer the following questions.

- 1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:*

	<i>No. of patients</i>
<i>CAPOX (Capecitabine with Oxaliplatin)</i>	<i>≤5</i>
<i>FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)</i>	<i>Nil</i>
<i>Lonsurf (Trifluridine - tipiracil)</i>	<i>Nil</i>
<i>Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)</i>	<i>Nil</i>
<i>Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)</i>	<i>Nil</i>
<i>Any other systemic anti-cancer therapy</i>	<i>≤5</i>
<i>Palliative care only</i>	<i>Nil</i>

Answer: Please see table above representing the latest 3 months 01 September 2022 to 30 November 2022.

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

	No. of patients
Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)	7
Nivolumab monotherapy	Nil
Nivolumab and Ipilimumab	≤5
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	Nil
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	≤5
Any other systemic anti-cancer therapy	38
Palliative care only	Nil

Answer: Please see table above representing the latest 3 months 01 September 2022 to 30 November 2022.

3. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

	No. of patients
Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)	6
Nivolumab monotherapy	Nil
Nivolumab and Ipilimumab	Nil
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	Nil
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	≤5
Any other systemic anti-cancer therapy	16
Palliative care only	≤5

Answer: Please see table above representing the latest 3 months 01 September 2022 to 30 November 2022.

4. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.

Answer: The Trust does not have active trials for gastric cancer at this time.

5. *Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients*

Answer: The Trust does not have active trials for oesophageal cancer at this time.